Researchers examined results from 522 patients during the study. Compared to the FDA-approved mSEPT9 blood test, Freenome’s test had a higher sensitivity (41 percent to 22 percent).
Compared to stool-based tests, Freenome’s sensitivity for advanced adenomas outperformed fecal immunochemical testing (24 percent) and was comparable to FIT-DNA testing (42 percent).
The new results supplement previously reported data that showed Freenome’s test detected stage 1 and stage 2 CRC at a sensitivity of 94 percent and a specificity of 94 percent.
More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don’t
Stryker’s ASC-focused business: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.